Daprodustat
CAS No. 960539-70-2
Daprodustat ( GSK-1278863 | GSK 1278863 )
产品货号. M16862 CAS No. 960539-70-2
一种新型口服活性 HIF-脯氨酰羟化酶 (PHD) 抑制剂,可刺激内源性 EPO 合成并通过非 EPO 作用诱导有效的红细胞生成。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥635 | 有现货 |
|
5MG | ¥979 | 有现货 |
|
10MG | ¥1491 | 有现货 |
|
25MG | ¥3299 | 有现货 |
|
50MG | ¥4763 | 有现货 |
|
100MG | 获取报价 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Daprodustat
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种新型口服活性 HIF-脯氨酰羟化酶 (PHD) 抑制剂,可刺激内源性 EPO 合成并通过非 EPO 作用诱导有效的红细胞生成。
-
产品描述A nove, orally active HIF-prolyl hydroxylase (PHD) inhibitor that stimulate endogenous EPO synthesis and induces effective erythropoiesis by non-EPO effects; shows potential for the treatment of anemia associated with chronic kidney disease.Anemia Phase 3 Clinical(In Vitro):GSK1278863 is an orally administered small-molecule PHI, and stimulates endogenous EPO synthesis and induce effective erythropoiesis. GSK1278863 has been shown to increase erythropoietin levels, leading to increases in hemoglobin, hematocrit and red blood cell numbers.
-
体外实验GSK1278863 is an orally administered small-molecule PHI, and stimulates endogenous EPO synthesis and induce effective erythropoiesis. GSK1278863 has been shown to increase erythropoietin levels, leading to increases in hemoglobin, hematocrit and red blood cell numbers.
-
体内实验——
-
同义词GSK-1278863 | GSK 1278863
-
通路Angiogenesis
-
靶点HIF/HIF Prolyl-hydroxylase
-
受体HIF-PH
-
研究领域Other Indications
-
适应症Anemia
化学信息
-
CAS Number960539-70-2
-
分子量393.4342
-
分子式C19H27N3O6
-
纯度>98% (HPLC)
-
溶解度DMSO: < 6.8 mg/mL
-
SMILESO=C(O)CNC(C(C(N1C2CCCCC2)=O)C(N(C3CCCCC3)C1=O)=O)=O
-
化学全称Glycine, N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Brigandi RA, et al. Am J Kidney Dis. 2016 Jun;67(6):861-71.
2. Hara K, et al. Drug Metab Pharmacokinet. 2015 Dec;30(6):410-8.
3. Johnson BM, et al. Clin Pharmacol Drug Dev. 2014 Mar;3(2):109-17.